Multiple Myeloma (MM) Research Group
The MM research group has two parts: a clinical component, largely involved in the treatment of patients at all stages of the disease and in clinical research activities through the promotion and conduct of national and international clinical trials; and a laboratory counterpart, dedicated to translational research in the field of molecular biology, with the support of a group of bio-informaticians.
Research field:
Clinical research on Multiple Myeloma (MM)
- First-line therapy with innovative drugs for patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT): design and coordination of independent Phase II and Phase III clinical trials, based on the integration of new drugs with autologous transplantation.
- Innovative therapeutic strategies and adoptive cellular immunotherapy (CAR-T cells: Chimeric Antigen Receptor T cells)).
- Novel imaging methods: diagnostics, prognosis prediction, and evaluation of metabolic response to therapy.
- Integrated approach to the hematological patient.
The treatment of MM has changed dramatically in recent years, thanks to the development of new drugs and therapeutic approaches. Intense activity in translational, clinical, and pharmacological research has enriched MM therapy with new non-chemotherapeutic drugs which act directly against tumor cells in the bone marrow microenvironment. Some of these new drugs have now entered daily clinical practice, while others are in earlier stages of development and are being used in clinical trials by specially trained personnel in order to test their toxicity and efficacy.
Clinical research is well established at the Institute of Hematology "Seràgnoli", a national and international hub for the management and treatment of MM patients. The Institute is also a reference center for the numerous clinical trials aimed at improving the clinical experience of patients with MM (over 30 active drug trials, Phases I–III), thereby granting outstanding treatment options with the most advanced drugs, while maintaining a consistently high standard of patient care.
In particular, the MM group is at the center of several international clinical trials sponsored by pharmaceutical companies for the use of new drugs (interventional and observational clinical trials in Phases I–III), retrospective studies on the use in daily clinical practice of therapies approved by AIFA, and studies aimed at defining the role of high-dose chemotherapy with stem cell support (prospective Phase III studies).
In addition, "Seràgnoli" Hematology - the Center in Emilia-Romagna for advanced CAR-T (therapies - has been an Italian pioneer in cutting-edge experimental clinical protocols for immunotherapy treatment with CAR-T cells in patients affected by MM.
Further investigations concern the study of genetic-molecular prognostic factors and markers of minimal residual disease (MRD), evaluated with modern molecular biology and functional imaging methods.
The research group organizes scientific events at the national and international levels, takes part in the direction of national organizations, and is actively involved in the definition of national and international guidelines and recommendations regarding MM.
Translational Research on MM:
- Molecular characterization of patients with MM at diagnosis and at relapse, study of the dynamics of clonal evolution during treatment and its correlation with resistance to therapy.
- Monitoring the dynamics of minimal residual disease during therapy with high resolution technologies: IgH-NGS on bone marrow aspirate, ULP-WGS on liquid biopsy (ctDNA), FC of CMMCs (circulating MM cells).
- Identification of prognostic factors associated with the clinical course of MM or predictive factors for the response to particular therapeutic regimens.
- Hub center in Italy for the evaluation of MRD and creation of an Italian network for the harmonization of methods for the molecular evaluation by NGS of Minimal Residual Disease in the daily clinical practice of MM.
- Validation of a targeted panel for the diagnostic framing of patients with MM, through the evaluation of translocations, numerical alterations, and point mutations (AIO panel, All-In-One).
- Study of clonal hematopoiesis using single-cell technology.
principal investigators
-
Elena Zamagni
Associate Professor
Dipartimento di Scienze Mediche e Chirurgiche - DIMEC
Via Massarenti 9
Bologna (BO)
Phone
-
Dott.ssa Carolina Terragna
Executive biologist
Laboratory of Molecular Biology
Department of Specialty, Diagnostic and Experimental Medicine
Via Massarenti 9 Bologna (BO)
TEAM
- vincenza.solli2@unibo.it
- tel: +39 051 2143973
Collaborators
The clinical-care and clinical research group is composed of:
Elena Zamagni, Associate Professor, Medical director, Head of the Multiple Myeloma Program
Paola Tacchetti, Medical Director
Lucia Pantani, Medical Director
Katia Mancuso, Research fellow
Serena Rocchi, PhD student
Ilaria Rizzello, PhD student
Alessio Fusco, Resident physician in Hematology
Gabriella De Cicco, Resident physician in Hematology
Margherita Ursi, Resident physician in Hematology
Emanuele Favero, Resident physician in Hematology
The “Molecular Biology laboratory” group is composed of:
Carolina Terragna, Senior biologist
Marina Martello, RTD
Enrica Borsi, RTD
Vincenza Solli, PhD student
Andrea Poletti, Research fellow
The "design and management of clinical studies" group is composed of:
Simona Barbato, Research fellow
Federica Pedali, Research fellow
Giorgia Lazzarini, Research fellow
Alessandra Scatà, Research fellow
Francesca Michela Trombetta, Research fellow
Giada Giulia Riso, Research fellow
Claudio Mostaccio, Research fellow
The Laboratory Group of Molecular Biology is involved in numerous collaborations, national and international, and actively participates in research projects funded by: AIRC - Call IG 2014 and Call IG 2018 (PI Prof. Michele Cavo), Ministry of Health - Ricerca Finalizzata 2016 (PI Prof. Michele Cavo), EMN Research Italy funding (PI Dr. Carolina Terragna).